TFF Pharmaceuticalsの空売り状況は、投資家がTFF Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

TFF Pharmaceuticals (NASDAQ:TFFP) 株価情報, 空売り情報

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

TFF Pharmaceuticals Inc

<p><strong>Spectrum Brands Holdings, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Friday.</a></p>
<p>The company reported fourth-quarter adjusted earnings per share of 97 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004018/spectrum-brands-holdings-reports-fiscal-2024-fourth-quarter" rel="noreferrer noopener">missing the street view of $1.07</a>. Quarterly revenues were $773.7 million (+4.5%), beating the analyst consensus of $747.51 million.</p>
<p>Gross profit surged 17.8% to $288 million. Gross profit and margin increased due to productivity improvements, operational efficiencies, and inventory actions in the prior year, partially offset by ocean freight inflation.</p>
<p>Adjusted EBITDA decreased $42.6 million, driven by $32.5 million of lower investment income and $25.9 million of increased brand-focused investments, offset by gross profit improvements.</p>
<p>As of the fiscal year-end, the company reported a cash balance of $369 million and total liquidity of $860 million, including undrawn capacity on its cash flow revolver.</p>
<p>It had $578 million in outstanding debt, consisting of $496 million in senior unsecured notes and around $82 million in finance lease obligations, resulting in a net debt of approximately $209 million.</p>
<p><strong>Outlook: </strong>Spectrum Brands expects low single-digit growth in reported net sales in fiscal 2025 and adjusted EBITDA to increase by mid to high single-digits. Adjusted free cash flow is expected to be approximately<a href="https://www.benzinga.com/calendars/guidance"> 50% of adjusted EBITDA.</a></p>
<p>The company continues to target a long-term net leverage ratio of 2.0 &#8211; 2.5 times.</p>
<p>&#8220;I am excited about the upcoming year. Our focus during fiscal 2025 will be to continue the momentum we built in fiscal 2024 by investing in our brands to drive long-term growth, in innovation to expand core and adjacent categories, and in our operations to drive further cost improvement, quality and safety,&#8221; said David Maura, Chairman and Chief Executive Officer of Spectrum Brands.</p>
<p><strong>Price Action:</strong> SPB shares are trading lower by 4.78% to $89.38&nbsp;at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42012197/totalenergies-joins-bp-equinor-and-shell-in-500m-drive-for-global-energy-access\" target="_blank" rel="noreferrer noopener">TotalEnergies Joins BP, Equinor, And Shell In $500M Drive For Global Energy Access</a></strong></li>
</ul>


Earnings

Equities

News

Guidance

Markets

Movers

General

Spectrum Brands Stock Falls After Q4 Earnings Miss On Lower Investment Income: Details

<p>Raymond James  analyst Michael Barth   reiterates Enerflex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFX#TSX">EFX</a>) with a Outperform and raises the price target from C$12 to C$13.75.</p>


Price Target

Reiteration

Analyst Ratings

TSX:EFX

Raymond James Reiterates Outperform on Enerflex, Raises Price Target to C$13.75

<p>RBC Capital  analyst Matthew McKellar   reiterates Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Outperform and maintains $58 price target.</p>


RBC Capital Reiterates Outperform on Smurfit WestRock, Maintains $58 Price Target

<p>Some large European and U.S. vaccine maker stocks have fallen in reaction to <strong>Robert F. Kennedy Jr.&#8217;s</strong> nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.</p>
<p>Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.</p>
<p>Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.</p>
<p>Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.</p>
<p>In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;</p>
<p>On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.</p>
<p>European vaccine player stocks declined, including&nbsp;<strong>GSK Plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), <strong>Valneva SE</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), <strong>AstraZeneca Plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and <strong>Sanofi SA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).</p>
<p>GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.</p>
<p>COVID-19 vaccine players <strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a></strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a></strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.</p>
<p>Other vaccine players&#8217; stocks that are down include <strong>Merck &amp; Co Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and <strong>Inovio Pharmaceuticals, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).</p>
<p><strong>Price Action: </strong>GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></strong></li>
</ul>
<p><em>Photo by Vladimka production via Shutterstock</em></p>


Biotech

Large Cap

Eurozone

Health Care

Trading Ideas

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

WIIM

NDRA

ENDRA Life Sciences shares are trading lower. The company reported Q3 financial results.

<p>Raymond James  analyst Stephen Boland   maintains CI Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIX#TSX">CIX</a>) with a Outperform and raises the price target from C$22 to C$27.</p>


TSX:CIX

Raymond James Maintains Outperform on CI Financial, Raises Price Target to C$27

ALRN

Aileron Therapeutics shares are trading lower. The company reported Q3 financial results.

<p>RBC Capital  analyst Jimmy Shan   maintains Flagship Communities (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MHC#TSX">MHC</a>) with a Outperform and raises the price target from C$19 to C$20.</p>


TSX:MHC

TSX:MHC/U

RBC Capital Maintains Outperform on Flagship Communities, Raises Price Target to C$20

OMGA

Omega Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results and Piper Sandler cut its price target on the stock from $9 to $4.

ALUR

Allurion Technologies shares are trading lower after Chardan Capital downgraded the stock from Buy to Neutral.

<p>BMO Capital  analyst Ben Pham   maintains Boralex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BLX#TSX">BLX</a>) with a Outperform and lowers the price target from C$46 to C$45.</p>


TSX:BLX

BMO Capital Maintains Outperform on Boralex, Lowers Price Target to C$45

VUZI

Vuzix shares are trading lower after the company reported worse-than-expected Q3 financial results.

<p>Deep-pocketed investors have adopted a bearish approach towards Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TEM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Tempus AI. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 50% bearish. Among these notable options, 6 are puts, totaling $683,586, and 2 are calls, amounting to $99,000.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $55.0 for Tempus AI during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Tempus AI's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tempus AI's whale activity within a strike price range from $30.0 to $55.0 in the last 30 days. </p>
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731687434_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.8</td>
<td>$4.5</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$246.2K</td>
<td align="right">85</td>
<td align="right">500</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$6.3</td>
<td>$5.0</td>
<td>$5.4</td>
<td>$45.00</td>
<td>$225.7K</td>
<td align="right">85</td>
<td align="right">462</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$4.7</td>
<td>$4.3</td>
<td>$4.7</td>
<td>$52.00</td>
<td>$92.5K</td>
<td align="right">206</td>
<td align="right">200</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$9.2</td>
<td>$7.7</td>
<td>$9.2</td>
<td>$55.00</td>
<td>$63.4K</td>
<td align="right">10</td>
<td align="right">90</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$23.7</td>
<td>$22.0</td>
<td>$23.0</td>
<td>$30.00</td>
<td>$50.6K</td>
<td align="right">0</td>
<td align="right">44</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tempus AI</h3>
<p>Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.</p>
<p>After a thorough review of the options trading surrounding Tempus AI, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Tempus AI</h3>
<ul>
<li>With a trading volume of 572,433, the price of TEM is up by 0.32%, reaching $56.81.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $67.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $70.<br />
&#x2A; Reflecting concerns, an analyst from Stifel lowers its rating to Hold with a new price target of $65.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Behind the Scenes of Tempus AI's Latest Options Trends

<p>Deep-pocketed investors have adopted a bearish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 19% leaning bullish and 71% bearish. Among these notable options, 11 are puts, totaling $1,047,442, and 10 are calls, amounting to $2,142,826.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $140.0 for Trade Desk during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trade Desk's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trade Desk's significant trades, within a strike price range of $90.0 to $140.0, over the past month.</p>
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731687428_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$34.85</td>
<td>$34.25</td>
<td>$34.4</td>
<td>$90.00</td>
<td>$1.0M</td>
<td align="right">746</td>
<td align="right">301</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.5</td>
<td>$9.45</td>
<td>$9.45</td>
<td>$105.00</td>
<td>$608.5K</td>
<td align="right">16</td>
<td align="right">644</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$32.2</td>
<td>$32.0</td>
<td>$32.0</td>
<td>$92.50</td>
<td>$320.0K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$32.8</td>
<td>$31.05</td>
<td>$32.4</td>
<td>$92.50</td>
<td>$181.4K</td>
<td align="right">634</td>
<td align="right">100</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.2</td>
<td>$26.75</td>
<td>$27.09</td>
<td>$115.00</td>
<td>$162.8K</td>
<td align="right">486</td>
<td align="right">60</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>With a volume of 1,511,116, the price of TTD is down -1.1% at $124.49. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 90 days.</li>
</ul>
<h3>Professional Analyst Ratings for Trade Desk</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $109.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Trade Desk with a target price of $135.<br />
&#x2A; An analyst from DA Davidson persists with their Buy rating on Trade Desk, maintaining a target price of $134.<br />
&#x2A; An analyst from New Street Research has revised its rating downward to Sell, adjusting the price target to $86.<br />
&#x2A; An analyst from Benchmark downgraded its action to Sell with a price target of $57.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Trade Desk with a target price of $135. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Trade Desk

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Nike</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Nike.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 44% bullish and 52%, bearish.</p>
<p>Out of all of the special options we uncovered, 16 are puts, for a total amount of $888,906, and 9 are calls, for a total amount of $375,233.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $95.0 for Nike, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Nike's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Nike's significant trades, within a strike price range of $60.0 to $95.0, over the past month.</p>
<h3>Nike Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731687423_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.59</td>
<td>$2.53</td>
<td>$2.53</td>
<td>$75.00</td>
<td>$126.5K</td>
<td>16.5K</td>
<td>526</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.53</td>
<td>$2.46</td>
<td>$2.51</td>
<td>$75.00</td>
<td>$125.2K</td>
<td>16.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NKE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$3.35</td>
<td>$3.25</td>
<td>$3.35</td>
<td>$95.00</td>
<td>$82.7K</td>
<td>1.8K</td>
<td>1</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.1</td>
<td>$80.00</td>
<td>$67.7K</td>
<td>12.0K</td>
<td>222</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.08</td>
<td>$80.00</td>
<td>$67.0K</td>
<td>12.0K</td>
<td>111</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<p>Following our analysis of the options activities associated with Nike, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Nike Standing Right Now?</h3>
<ul>
<li>With a volume of 3,359,657, the price of NKE is up 0.86% at $76.33. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 34 days.</li>
</ul>
<h3>What Analysts Are Saying About Nike</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $80.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Nike with a target price of $80. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Nike, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of Nike's Latest Options Trends

<p><strong>Visa Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) stock has climbed following <strong>Donald Trump's</strong> <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election win</a>, driven by expectations of economic policies that could stimulate consumer spending and benefit payment processors like Visa.</p>
<p>Trump's proposal to extend and expand tax cuts is likely to increase disposable income for households and encourage corporate investment, leading to a surge in transaction volumes—Visa's primary revenue source.</p>
<p><strong>What Else:</strong> Additionally, Trump's deregulatory agenda could benefit Visa by reducing compliance costs in the financial sector, allowing the company to invest more aggressively in innovation. </p>
<p>This could accelerate Visa's development of digital payment technologies, enhance its global network, and foster partnerships with emerging fintech companies. Visa is well-positioned to capitalize on this growth as digital transactions continue to replace cash worldwide.</p>
<p>Trump's focus on economic expansion through infrastructure spending and trade reforms could further bolster Visa's business segment by increasing corporate transactions and cross-border payment activity. </p>
<p>Potential inflationary pressures under Trump's policies may also indirectly benefit Visa, as higher transaction values generate increased processing fees.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/42006281/alibaba-q2-earnings-revenue-beats-forecast-cloud-and-international-sales-shine-free-cash-flow-falls-amid-strategic-investments">Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments</a></strong></p>
<h2 class="wp-block-heading">Is V A Good Stock To Buy?</h2>
<p>An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages  &#8211; like <a href="https://www.benzinga.com/quote/V">Visa</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.</p>
<p>These are known as capital allocation programs. Visa does pay a dividend, which yields 0.78% per year as of the closing price on Nov. 15, 2024. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.</p>
<p>Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/V">Visa</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, V has a 52-week high of $312.44 and a 52-week low of $245.60.</p>


Why Visa Stock Hit A New 52-Week High This Week

The Oncology Institute shares are trading lower. The stock may be moving on continued weakness following worse-than-expected Q3 financial results reported on Wednesday.

<p>Nvidia CEO Jensen Huang and SoftBank&#8217;s Masayoshi Son recently shared a few laughs and some bittersweet memories at the AI Summit in Tokyo. At the center of their banter? SoftBank&#8217;s former role as Nvidia&#8217;s largest shareholder – and how they decided to let that golden opportunity slip away.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Billionaires Jensen Huang and Masayoshi Son joke about how SoftBank was once Nvidia&#39;s largest shareholder — before dumping its stake. <br /><br />The two are now joining forces on an AI supercomputer <a href="https://t.co/UjUIVaCinN">https://t.co/UjUIVaCinN</a> <a href="https://t.co/rfd1p1yKB0">pic.twitter.com/rfd1p1yKB0</a></p>
<p>&mdash; Bloomberg (@business) <a href="https://twitter.com/business/status/1856563439331618846?ref_src=twsrc%5Etfw">November 13, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"><strong> </strong><strong>here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</strong></a></strong></li>
<li><strong>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></li>
</ul>
<p>In 2019, SoftBank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) sold all of its Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares, which comprised about 4.9% of the company. It seemed like a solid move back then: they had invested around $700 million and ended up making $3.3 billion from the sale. But now, Son admits the decision wasn&#8217;t exactly a home run. Today, <a href="https://www.benzinga.com/general/24/06/39489510/the-150-billion-opportunity-softbank-lost-by-selling-nvidia-shares-too-soon">those shares would be worth over $150 billion</a>.</p>
<p>During their talk, Huang jokingly said, &#8220;We can cry together,&#8221; hugging Son on stage as they remembered what might have been. Son, not missing a beat, added that he had to &#8220;tearfully&#8221; sell those shares. Huang even shared that Son once offered him financial backing to buy Nvidia outright – something he now wishes he'd taken. &#8220;That was a great idea,&#8221; Huang said, with a hint of regret.</p>
<p><strong>Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"><strong> </strong><strong>invest today with $1,000 for just $0.25/share</strong></a></strong></p>
<p>Huang praised Son for being a visionary who has consistently backed winning innovators like Bill Gates, Jerry Yang and Steve Jobs. Son has a talent for recognizing big opportunities and helping establish major tech moments, from bringing Gates and Jobs to Japan to making Alibaba&#8217;s success possible in China. Yet, even with all those successes, the missed Nvidia chance still stings.</p>
<p>Today, <a href="https://www.benzinga.com/quote/NVDA">Nvidia is worth $3.6 trillion</a> and is the world&#8217;s most valuable company, ahead of tech giants like Apple and Microsoft. Its value has skyrocketed thanks to the AI boom, with its chips playing a crucial role in powering AI technologies across the globe. Nvidia&#8217;s stock has surged 2,768% in the last five years, putting <a href="https://www.benzinga.com/startups/24/11/41882908/640416">Jensen Huang&#8217;s net worth</a> at a staggering $127 billion.</p>
<p><strong>See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"><strong> </strong><strong>you can become an investor for $0.80 per share today.</strong></a></strong></p>
<p>SoftBank, meanwhile, remains heavily invested in the future of AI. Son has made it clear that he&#8217;s not done yet. He recently mentioned that his true purpose might be to <a href="https://www.benzinga.com/news/24/10/41181374/softbanks-masayoshi-son-predicts-artificial-superintelligence-within-a-decade-after-testing-openais">bring about artificial superintelligence (ASI) – </a>a form of AI that could be 10,000 times smarter than humans. His belief in the power of AI and its ability to solve global problems, from diseases to natural disasters, keeps driving him forward.</p>
<p>Despite the missed opportunity with Nvidia, SoftBank is moving ahead at full throttle. Son and Huang recently <a href="https://www.benzinga.com/news/global/24/11/41929194/nvidia-and-softbank-to-build-japans-top-ai-supercomputer-on-blackwell-platform-jensen-huang-says-tokyo-is-leaping-into-the-ai-industrial-revolution">announced a partnership</a> to build Japan&#8217;s most powerful AI supercomputer using Nvidia&#8217;s latest Blackwell chips. The goal? To establish Japan as a major player in AI, with applications that could transform industries like telecommunications, health care and transportation.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai"><strong>Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"><strong> </strong><strong>You can still get 4,000 of its pre-IPO shares for just $1,000</strong></a></strong></li>
</ul>


Startups

NVDA

SFTBF

Must See: Billionaires Jensen Huang And Masayoshi Son Joke About SoftBank's Past As Nvidia's Largest Shareholder – Before Dumping Its Stake

<p>RBC Capital  analyst Arthur Nagorny   maintains Mattr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MATR#TSX">MATR</a>) with a Outperform and lowers the price target from C$20 to C$18.</p>


TSX:MATR

RBC Capital Maintains Outperform on Mattr, Lowers Price Target to C$18

<p><strong>Mullen Automotive, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are trading lower on Friday. The company partnered with <strong>National Auto Fleet Group</strong> (NAFG) to sell its all-electric Class 4 Bollinger B4 commercial <a href="https://www.benzinga.com/pressreleases/24/11/g42008604/mullen-subsidiary-bollinger-motors-partners-with-national-auto-fleet-group-for-government-fleet-ve" target="_blank" rel="noreferrer noopener">trucks to government agencies</a>.</p>
<p>The Bollinger B4 Chassis Cab, a fully electric Class 4 commercial truck, offers a range of 185 miles and a payload capacity of 7,394 pounds.</p>
<p>The Bollinger B4 is ideal for commercial, government, and municipal fleets seeking a versatile, high-performance truck for a variety of tasks.</p>
<p>Bollinger CRO <strong>Jim Connelly</strong> said, &#8220;Government agencies and municipalities are often early adopters for electrification and electric vehicle fleets. We look forward to partnering with NAFG, and their history of bringing innovative products and solutions to this important segment.&#8221;</p>
<p>Mullen announced its Class 1 EV cargo van, the Mullen ONE, is available for rent on Turo, a vehicle-sharing marketplace. The effort is in collaboration with Parasol Strategic Solutions,<a href="https://www.benzinga.com/trading-ideas/movers/24/11/41913722/whats-going-on-with-mullen-automotive-stock-tuesday-2" target="_blank" rel="noreferrer noopener"> a high-level Turo host based in Florida</a>.</p>
<p>Last month, Bollinger Motors completed its first West Coast delivery of 2025 <a href="https://www.benzinga.com/markets/equities/24/10/41630662/mullens-bollinger-motors-marks-milestone-with-500-thousand-west-coast-ev-truck-delivery" target="_blank" rel="noreferrer noopener">Bollinger B4 trucks worth ~$500K</a>.</p>
<p>Also, Bollinger Motors completed its first customer delivery of the 2025&nbsp;Bollinger B4 Chassis Cab, generating $800,000 in revenue for the <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41166786/whats-going-on-with-mullen-automotive-stock-thursday" rel="noreferrer noopener">original equipment manufacturer</a>.</p>
<p><strong>Price Action</strong>: Mullen Automotive shares are down 9.28% at $3.13, at the last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com//node/42011035" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></strong></li>
</ul>
<p><em>Image: Courtesy of Mullen Automotive</em></p>


Contracts

Small Cap

MULN

Mullen Drives Into Government Sector With Electric Bollinger B4 Trucks

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TFF Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>TFF Pharmaceuticals reported earnings per share of -$2.40. This was below the analyst estimate for EPS of -$2.26.</li><li>The company reported revenue of $203,273.</li><li>This was 190.39% better than the analyst estimate for revenue of $70,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/tffp-stock-earnings-tff-pharmaceuticals-for-q1-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;</p>



<p>Bottom-picking <em>is</em> risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to <em>mitigate</em> those risks.&nbsp;</p>



<p>For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:</p>



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul><p>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;</p>



<p>This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. </p>



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a><p>The growing demand for EVs has spotlighted companies like <strong>Microvast Holdings </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/"><strong>MVST</strong></a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;</p>



<p>The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;</p>



<p>Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;</p>



<p>In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.</p>



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. <strong>TFF Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;</p>



<p>TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.</p>



<p>A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.</p>



<p>Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.</p>



<p>But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;</p>



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div><p>Formerly known as Knowledgetree Ventures, <strong>My Size</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/"><strong>MYSZ</strong></a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;</p>



<p>While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;</p>



<p>My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;</p>



<p>Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;</p>



<p><em>On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a>.</p>
<div><p>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TFF Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/tffp-stock-quote/"><strong>TFFP</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

TFF Pharmaceuticals to wind down operations

TFF Pharmaceuticals ( ($TFFP) ) has provided an announcement. TFF Pharmaceuticals, Inc. is set to dissolve following its board's approval of a liqu...

TFF Pharmaceuticals to Dissolve and Liquidate Assets

16:45 EST TFF Pharmaceuticals (TFFP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

TFF Pharmaceuticals trading resumes

MVST

MYSZ

TFFP

Press Releases

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

TFF Pharmaceuticals Announces It Will Wind Down Operations

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Artelo Biosciences

Aytu BioPharma

Biofrontera

Cingulate

CNS Pharma

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Hoth Therapeutics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NRX Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

ProPhase Labs

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Comments

TFF Pharmaceuticals

空売り

TFF Pharmaceuticals (NASDAQ:TFFP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル